Rezolute (RZLT) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Rezolute is scheduled to announce its Q4 2025 earnings on September 18th, with analysts expecting a loss of ($0.22) per share.
• Rezolute's stock recently opened at $8.10, with a market cap of $704.70 million and a PE ratio of -7.04.
• Insider buying activity includes Director Young-Jin Kim purchasing 1,230,769 shares, increasing their ownership by 17.11% and totaling nearly $4 million.

Rezolute (NASDAQ:RZLT - Get Free Report) is anticipated to issue its Q4 2025 results before the market opens on Thursday, September 18th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties may review the information on the company's upcoming Q4 2025 earningreport for the latest details on the call scheduled for Friday, September 19, 2025 at 4:00 PM ET.

Rezolute Stock Up 0.2%

Shares of NASDAQ:RZLT opened at $8.10 on Thursday. Rezolute has a fifty-two week low of $2.21 and a fifty-two week high of $8.34. The firm has a 50-day simple moving average of $6.24 and a 200 day simple moving average of $4.56. The company has a market cap of $704.70 million, a PE ratio of -7.04 and a beta of 0.03.

Analyst Ratings Changes

RZLT has been the subject of a number of analyst reports. Wall Street Zen lowered shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Wedbush reissued an "outperform" rating and set a $12.00 target price on shares of Rezolute in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of Rezolute in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $11.67.

Insider Buying and Selling at Rezolute

In other Rezolute news, Director Young-Jin Kim bought 1,230,769 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was acquired at an average cost of $3.25 per share, with a total value of $3,999,999.25. Following the completion of the purchase, the director directly owned 8,423,386 shares in the company, valued at approximately $27,376,004.50. This trade represents a 17.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders have purchased 1,241,345 shares of company stock valued at $4,041,196. Corporate insiders own 18.39% of the company's stock.

Institutional Investors Weigh In On Rezolute

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in Rezolute in the 2nd quarter valued at approximately $25,000. Legal & General Group Plc acquired a new position in Rezolute in the 2nd quarter valued at approximately $32,000. Raymond James Financial Inc. acquired a new position in Rezolute in the 2nd quarter valued at approximately $46,000. New York State Common Retirement Fund acquired a new position in Rezolute in the 2nd quarter valued at approximately $104,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Rezolute in the 2nd quarter valued at approximately $106,000. Institutional investors and hedge funds own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.